China Traditional Chinese Medicine Holdings Valuation

Q: What is the Fair Price of 570 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

570 (HK$2.26) is trading below our estimate of [[fair value]] (HK$32.69)

Is 570 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 570 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 570 (HK$2.26) is trading below our estimate of fair value (HK$32.69)

Significantly Below Fair Value: 570 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 570?

Key metric: As 570 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 570. This is calculated by dividing 570's market cap by their current earnings.
What is 570's PE Ratio?
PE Ratio	11.5x
Earnings	CN¥917.44m
Market Cap	CN¥10.59b

570 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	7.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 570's PE Ratio compare to its peers?

The above table shows the PE ratio for 570 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	10.2x
2005 SSY Group	8.3x	5.8%	HK$11.3b
2186 Luye Pharma Group	11.9x	22.0%	HK$9.9b
719 Shandong Xinhua Pharmaceutical	8.4x	n/a	HK$9.8b
867 China Medical System Holdings	12.4x	21.4%	HK$18.5b
570 China Traditional Chinese Medicine Holdings	11.5x	n/a	HK$11.4b

Price-To-Earnings vs Peers: 570 is expensive based on its Price-To-Earnings Ratio (11.5x) compared to the peer average (10.2x).

Price to Earnings Ratio vs Industry

How does 570's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 570 is expensive based on its Price-To-Earnings Ratio (11.5x) compared to the Hong Kong Pharmaceuticals industry average (8.4x).

Price to Earnings Ratio vs Fair Ratio

What is 570's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

570 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	11.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 570's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

3SBio

HK$13.8b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.69

-2.4%

-23.1%

Consun Pharmaceutical Group

HK$7.0b

Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.

1681

HK$8.45

-0.7%

82.1%

United Laboratories International Holdings

HK$18.3b

An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.

3933

HK$10.06

-1.9%

25.9%